CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient. The company is also developing CTX101, a donor-derived gene-edited allogeneic CAR-T therapy targeting CD19-positive malignancies. In addition, it is developing earlier stage allogeneic CAR-T programs targeting B-Cell maturation antigen and CD70; hemoglobinopathies to treat other diseases, including Hurler Syndrome and severe combined immunodeficiency disease; programs that are in preclinical development for indications, including glycogen storage disease Ia and hemophilia; and programs targeting diseases of organ systems outside the liver, such as Duchenne muscular dystrophy and cystic fibrosis. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated Vertex Pharmaceuticals (Europe) Limited to develop, manufacture, commercialize, sell, and use therapeutics. The company also has research collaboration agreements with Neon Therapeutics for developing neoantigen-based therapeutic vaccines and T cell therapies; and Massachusetts General Hospital Cancer Center to develop T cell therapies for cancer. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CRSP
CUSIPN/A
Phone41-61-228-7800
Debt
Debt-to-Equity RatioN/A
Current Ratio17.89
Quick Ratio17.89
Price-To-Earnings
Trailing P/E Ratio-28.83
Forward P/E Ratio-16.84
P/E GrowthN/A
Sales & Book Value
Annual Sales$41 million
Price / Sales56.49
Cash FlowN/A
Price / CashN/A
Book Value$4.09 per share
Price / Book11.90
Profitability
EPS (Most Recent Fiscal Year)($1.71)
Net Income$-68,350,000.00
Net Margins-245.57%
Return on Equity-39.58%
Return on Assets-28.49%
Miscellaneous
Employees127
Outstanding Shares47,590,000
Market Cap$2.24 billion
Crispr Therapeutics (NASDAQ:CRSP) Frequently Asked Questions
What is Crispr Therapeutics' stock symbol?
Crispr Therapeutics trades on the NASDAQ under the ticker symbol "CRSP."
How were Crispr Therapeutics' earnings last quarter?
Crispr Therapeutics AG (NASDAQ:CRSP) issued its quarterly earnings results on Wednesday, August, 8th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.63) by $0.19. The firm earned $1.09 million during the quarter, compared to analyst estimates of $1.47 million. Crispr Therapeutics had a negative return on equity of 39.58% and a negative net margin of 245.57%. View Crispr Therapeutics' Earnings History.
When is Crispr Therapeutics' next earnings date?
What price target have analysts set for CRSP?
9 brokerages have issued 1-year price targets for Crispr Therapeutics' shares. Their forecasts range from $51.00 to $86.00. On average, they expect Crispr Therapeutics' stock price to reach $65.1714 in the next year. This suggests a possible upside of 34.2% from the stock's current price. View Analyst Price Targets for Crispr Therapeutics.
What is the consensus analysts' recommendation for Crispr Therapeutics?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Crispr Therapeutics in the last year. There are currently 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Crispr Therapeutics.
What are Wall Street analysts saying about Crispr Therapeutics stock?
Here are some recent quotes from research analysts about Crispr Therapeutics stock:
- 1. According to Zacks Investment Research, "CRISPR Therapeutics AG is a gene-editing company. It focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR Therapeutics AG is headquartered in Basel, Switzerland. " (8/10/2018)
- 2. Cann analysts commented, "CRISPR Therapeutics presented updated preclinical data on CTX001, a CRISPR gene-editing therapy for beta-thalassemia and sickle cell disease, at the 2017 American Society of Hematology meeting. These data are highly supportive of the upcoming phase I clinical development program in beta-thalassemia, which is on track to begin in 2018." (12/10/2017)
Who are some of Crispr Therapeutics' key competitors?
Some companies that are related to Crispr Therapeutics include Qiagen (QGEN), bluebird bio (BLUE), AveXis (AVXS), BIO-TECHNE (TECH), Ablynx (ABLYF), China Biologic Products (CBPO), Aerie Pharmaceuticals (AERI), argenx (ARGX), Halozyme Therapeutics (HALO), Spark Therapeutics (ONCE), Acceleron Pharma (XLRN), Regenxbio (RGNX), Repligen (RGEN), Momenta Pharmaceuticals (MNTA) and Rubius Therapeutics (RUBY).
Who are Crispr Therapeutics' key executives?
Crispr Therapeutics' management team includes the folowing people:
- Dr. Rodger Novak, Founder & Chairman (Age 51)
- Dr. Kala Subramanian Ph.D., Chief of Staff and Sr. VP of Strategic Devel. & Operations (Age 51)
- Dr. N. Anthony Coles Jr., Sr. Advisor (Age 58)
- Dr. Samarth Kulkarni, Chief Exec. Officer (Age 39)
- Dr. Chad Cowan, Scientific Founder
When did Crispr Therapeutics IPO?
(CRSP) raised $75 million in an initial public offering (IPO) on Wednesday, October 19th 2016. The company issued 4,700,000 shares at $15.00-$17.00 per share. Citigroup, Piper Jaffray and Barclays served as the underwriters for the IPO and Guggenheim Securities was co-manager.
Has Crispr Therapeutics been receiving favorable news coverage?
Press coverage about CRSP stock has been trending somewhat positive recently, Accern reports. The research group identifies negative and positive press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Crispr Therapeutics earned a media and rumor sentiment score of 0.09 on Accern's scale. They also gave headlines about the company an impact score of 47.01 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days. View Recent Headlines for Crispr Therapeutics.
Who are Crispr Therapeutics' major shareholders?
Crispr Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Versant Venture Management LLC (7.65%), NEA Management Company LLC (4.43%), Federated Investors Inc. PA (1.34%), BlackRock Inc. (1.26%), Orbimed Advisors LLC (1.04%) and ARK Investment Management LLC (0.99%). Company insiders that own Crispr Therapeutics stock include Aktiengesellschaft Bayer, Bradley J Phd Bolzon, Corp /De/ Celgene, Kurt Von Emster, Pablo J Cagnoni, Rodger Novak, Samarth Kulkarni, Simeon George, Thomas Woiwode, Tyler Dylan-Hyde and Versant Venture Capital V, LP. View Institutional Ownership Trends for Crispr Therapeutics.
Which institutional investors are selling Crispr Therapeutics stock?
CRSP stock was sold by a variety of institutional investors in the last quarter, including NEA Management Company LLC, Versant Venture Management LLC, Wells Fargo & Company MN, Global Thematic Partners LLC, Capital Advisors Inc. OK, First Allied Advisory Services Inc., CIBC World Markets Inc. and EAM Global Investors LLC. Company insiders that have sold Crispr Therapeutics company stock in the last year include Bradley J Phd Bolzon, Corp /De/ Celgene, Kurt Von Emster, Pablo J Cagnoni, Rodger Novak, Samarth Kulkarni, Thomas Woiwode, Tyler Dylan-Hyde and Versant Venture Capital V, LP. View Insider Buying and Selling for Crispr Therapeutics.
Which institutional investors are buying Crispr Therapeutics stock?
CRSP stock was acquired by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, ARK Investment Management LLC, Orbimed Advisors LLC, FMR LLC, Renaissance Technologies LLC, First Trust Advisors LP, Korea Investment CORP and Frontier Capital Management Co. LLC. Company insiders that have bought Crispr Therapeutics stock in the last two years include Aktiengesellschaft Bayer, Corp /De/ Celgene and Simeon George. View Insider Buying and Selling for Crispr Therapeutics.
How do I buy shares of Crispr Therapeutics?
Shares of CRSP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Crispr Therapeutics' stock price today?
One share of CRSP stock can currently be purchased for approximately $48.58.
How big of a company is Crispr Therapeutics?
Crispr Therapeutics has a market capitalization of $2.24 billion and generates $41 million in revenue each year. The company earns $-68,350,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis. Crispr Therapeutics employs 127 workers across the globe.
How can I contact Crispr Therapeutics?
Crispr Therapeutics' mailing address is BAARERSTRASSE 14, ZUG V8, CH-6300. The company can be reached via phone at 41-61-228-7800.
MarketBeat Community Rating for Crispr Therapeutics (NASDAQ CRSP)
MarketBeat's community ratings are surveys of what our community members think about Crispr Therapeutics and other stocks. Vote "Outperform" if you believe CRSP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRSP will underperform the S&P 500 over the long term. You may vote once every thirty days.
